|
|
 |
|
Viewing report
|
|
|
|
Bulletin: Endo Pharmaceuticals Rating Not Affected By Expected Supply Constraints Jan 12
Standard & Poors, Jan 2012
Abstract
BOSTON (Standard & Poor's) Jan. 10, 2012--Standard & Poor's Ratings Services said today that Endo Pharmaceutical Holdings Inc.'s (BB/Stable/--) announcement that potential short-term supply constraints of certain analgesic medications, following a temporary shut down of a Novartis facility, will not affect its rating or outlook on the company. Although the exact timing of the shutdown is not known at this time, we believe efforts to move some production from the affected facility to in-house production facilities, and the already planned shift to Grunenthal Pharma for production of crush-resistant Opana ER, should help minimize the disruption. Our rating on Chadds Ford, Penn.-based Endo Pharmaceuticals Holdings Inc. reflects the company's 'significant' financial risk (as our criteria define the term) following its completion...
Companies mentioned in this report are: Endo Pharmaceuticals Holdings Inc.
Action: Bulletin
Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.
Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.
|
|
|
|
